NCT06970626 Quality of Recovery in Laparoscopic Sleeve Gastrectomy Using Dexmedetomidine Infusion Versus Laparoscopic TAP Block in Combination With Paragastric Neural Block
| NCT ID | NCT06970626 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Alexandria University |
| Condition | Laparoscopic Sleeve Gastrectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-04-03 |
| Primary Completion | 2025-06-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 60 participants in total. It began in 2025-04-03 with a primary completion date of 2025-06-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn which is better, combining Dexmedetomidine infusion and paragastric neural block or combining laparoscopic TAP block and paragastric neural block to enhance recovery after laparoscopic sleeve gastrectomy. The main questions it aims to answer are: Will using paragastric neural block (PGNB) combined with dexmedetomidine infusion give better recovery or using PGNB combined with laparoscopic transversus abdominis plane (LTAP) block in patients undergoing laparoscopic sleeve gastrectomy. This will be assessed by: Recording how much opioids were consumed by the patients Hemodynamic stability of the enrolled patients Pain scores as given by the patient The quality of postoperative patient recovery How many patients encountered nausea or vomiting
Eligibility Criteria
Inclusion Criteria: 1. American Society of Anesthesiologists (ASA) physical status II- III 2. BMI 35- 50 kg/m2 Exclusion Criteria: 1. Significant hepatic, renal, neuromuscular, or cardiac impairments 2. Extreme obesity (BMI \> 50 kg/m2) 3. Patients on current opioid medication 4. Allergies to dexmedetomidine or bupivacaine
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06970626 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 60 Years, studying Laparoscopic Sleeve Gastrectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06970626 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06970626 currently recruiting?
Yes, NCT06970626 is actively recruiting participants. Contact the research team at m_mohamed165@alexmed.edu.eg for enrollment information.
Where is the NCT06970626 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT06970626 clinical trial?
NCT06970626 is sponsored by Alexandria University. The trial plans to enroll 60 participants.